Literature DB >> 8589923

Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

A Dietrich1, Y Kawakubo, B Rzany, M Mockenhaupt, J C Simon, E Schöpf.   

Abstract

Low constitutive N-acetylating capacity has been implicated as a predisposing factor for the development of adverse reactions to certain drugs. This prompted us to investigate whether the N-acetylating capacity of patients with serious cutaneous adverse reactions, i.e., Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) differed from that of healthy control subjects. N-acetylating activity was measured in hair root cells by preparing a homogenate from freshly extracted hair roots and assessing acetyl-CoA-dependent N-acetylation by RP-HPLC using 2-aminofluorene as a substrate. Samples were obtained from hospitalized patients suffering from acute SJS and TEN or from healthy controls. All patients with SJS and TEN were found to have a low N-acetylating capacity (0.85 nmol/mg/min compared to 2.21 nmol/mg/min in controls, p < 0.05). Based on these findings, a low constitutive N-acetylating capacity may be one of the predisposing factors for the development of serious cutaneous adverse reactions to drugs that require N-acetylation in these patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589923     DOI: 10.1111/j.1600-0625.1995.tb00211.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  9 in total

1.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 2.  [Emergencies in allergology].

Authors:  C Bauer; F Ruëff; B Przybilla
Journal:  Hautarzt       Date:  2004-06       Impact factor: 1.198

Review 3.  Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.

Authors:  Audrey Jacobsen; Bayanne Olabi; Annie Langley; Jennifer Beecker; Eric Mutter; Amanda Shelley; Brandon Worley; Timothy Ramsay; Arturo Saavedra; Roses Parker; Fiona Stewart; Jordi Pardo Pardo
Journal:  Cochrane Database Syst Rev       Date:  2022-03-11

Review 4.  Toxic epidermal necrolysis.

Authors:  Wolfram Hoetzenecker; Tarun Mehra; Ieva Saulite; Martin Glatz; Peter Schmid-Grendelmeier; Emmanuella Guenova; Antonio Cozzio; Lars E French
Journal:  F1000Res       Date:  2016-05-20

5.  Stevens-Johnson Syndrome Patient Received Combination Chemotherapy Gemcitabine, Cisplatin, and 5-FU for Biliary Tract Cancer.

Authors:  Mozaffar Aznab; Mansour Khazaei
Journal:  Iran J Cancer Prev       Date:  2016-06-13

6.  Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa.

Authors:  Antoinette V Chateau; Ncoza C Dlova; Halima Dawood; Colleen Aldous
Journal:  South Afr J HIV Med       Date:  2019-07-04       Impact factor: 2.744

7.  Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype.

Authors:  Dora Janeth Fonseca; Adrien Morel; Kevin Llinás-Caballero; David Bolívar-Salazar; Paul Laissue
Journal:  Pharmgenomics Pers Med       Date:  2021-03-01

Review 8.  Adverse cutaneous drug eruptions: current understanding.

Authors:  W Hoetzenecker; M Nägeli; E T Mehra; A N Jensen; I Saulite; P Schmid-Grendelmeier; E Guenova; A Cozzio; L E French
Journal:  Semin Immunopathol       Date:  2015-11-09       Impact factor: 11.759

9.  Correlation between drug-drug interaction-induced Stevens-Johnson syndrome and related deaths in Taiwan.

Authors:  Fu-Jen Cheng; Fei-Kai Syu; Kuo-Hsin Lee; Fu-Cheng Chen; Chien-Hung Wu; Chien-Chih Chen
Journal:  J Food Drug Anal       Date:  2016-01-14       Impact factor: 6.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.